title: Loss expression of PHLPP1 correlates with lymph node metastasis and exhibits a poor prognosis in patients with gastric cancer.
abstract: BACKGROUND
  PHLPP1 functions as an antitumor factor in several human cancers, but the expression pattern and clinical significance of PHLPP1 in gastric cancer have yet to be determined. The aim of this study is to assess the expression of PHLPP1 in gastric cancer and its impact on the prognosis of patients with gastric cancer.
  
  
  METHODS
  A total of 202 consecutive patients with gastric cancer who had undergone gastrectomy were enrolled in this study. The expressions of PHLPP1 were assessed by immunohistochemistry method. Survival analysis according to PHLPP1 expression was calculated.
  
  
  RESULTS
  The positive rates of PHLPP1 protein in primary gastric cancer tissues and metastatic lymph nodes were significantly lower than in normal stomach mucosa tissues (56.9% vs. 96.7%, 38.8% vs. 96.7%, both P < 0.001). The overall survival (OS) time and relapse-free survival (RFS) time in PHLPP1-positive patients were significantly longer than in PHLPP1-negative patients (both P < 0.001). Moreover, PHLPP1 was an independent prognostic factor for OS and RFS of gastric cancer patients (HR 0.55, 95% CI 0.36-0.85, P = 0.007; HR 0.52, 95% CI 0.31-0.87, P = 0.013; respectively).
  
  
  CONCLUSIONS
  The loss expression of PHLPP1 was observed in gastric cancer and PHLPP1 is an independent prognostic factor for patients with gastric cancer.
authors.affiliation: Department of Gastrointestinal Surgery and Centre of Gastric Cancer, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, People's Republic of China.
authors.forename: Zhixiong
authors.initials: Z
authors.lastname: Wang
authors.forename: Haihua
authors.initials: H
authors.lastname: Shu
authors.forename: Zhao
authors.initials: Z
authors.lastname: Wang
authors.forename: Guanghua
authors.initials: G
authors.lastname: Li
authors.forename: Ji
authors.initials: J
authors.lastname: Cui
authors.forename: Hui
authors.initials: H
authors.lastname: Wu
authors.forename: Shirong
authors.initials: S
authors.lastname: Cai
authors.forename: Weiling
authors.initials: W
authors.lastname: He
authors.forename: Yulong
authors.initials: Y
authors.lastname: He
authors.forename: Wenhua
authors.initials: W
authors.lastname: Zhan
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D005743:Gastrectomy; D005753:Gastric Mucosa / Q000201:enzymology; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000096:biosynthesis* / Q000172:deficiency / Q000378:metabolism; D010749:Phosphoprotein Phosphatases / Q000096:biosynthesis* / Q000172:deficiency / Q000378:metabolism; D011379:Prognosis; D016016:Proportional Hazards Models; D013274:Stomach Neoplasms / Q000201:enzymology* / Q000473:pathology* / Q000601:surgery; D015996:Survival Rate
chemical_list: D009687:Nuclear Proteins; C400601:PHLPP1 protein, human; D010749:Phosphoprotein Phosphatases
keywords: PHLPP1; gastric cancer; overall survival (OS); prognosis; relapse-free survival (RFS)